| __timestamp | Lantheus Holdings, Inc. | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 72429000 | 11606000000 |
| Thursday, January 1, 2015 | 78634000 | 10313000000 |
| Friday, January 1, 2016 | 75374000 | 9762000000 |
| Sunday, January 1, 2017 | 92157000 | 9830000000 |
| Monday, January 1, 2018 | 93326000 | 10102000000 |
| Tuesday, January 1, 2019 | 103132000 | 10615000000 |
| Wednesday, January 1, 2020 | 110171000 | 8955000000 |
| Friday, January 1, 2021 | 218817000 | 9634000000 |
| Saturday, January 1, 2022 | 233827000 | 10042000000 |
| Sunday, January 1, 2023 | 267194000 | 10504000000 |
Cracking the code
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Merck & Co., Inc. and Lantheus Holdings, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Merck's SG&A expenses have shown a slight decline, with a notable dip in 2020, reflecting a strategic tightening of their budget. In contrast, Lantheus Holdings has seen a steady increase, with a significant 270% rise from 2014 to 2023. This divergence highlights Merck's focus on cost efficiency, while Lantheus appears to be investing more in growth and expansion. As the industry evolves, these strategies will play a pivotal role in shaping their financial futures. Understanding these trends offers valuable insights into how major players navigate economic challenges and opportunities.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Merck & Co., Inc.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Novartis AG
Merck & Co., Inc. vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
Merck & Co., Inc. and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Merck & Co., Inc. vs Merus N.V. Trends and Insights
Comparing SG&A Expenses: Merck & Co., Inc. vs Perrigo Company plc Trends and Insights
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Geron Corporation
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Evotec SE Trends and Insights
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Lantheus Holdings, Inc.
Genmab A/S and Lantheus Holdings, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated